Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Buy up to $2B of Notes

NEW YORK – Roche said on Tuesday it has commenced a tender offer to purchase for cash a combined aggregate purchase price of up to $2 billion of certain notes.

The notes being purchased include 7 percent notes due 2039; 3.35 percent notes due 2024; 3.25 percent notes due 2023; 3 percent notes due 2025; 2.875 percent notes due 2021; and 5.25 percent senior notes due 2035. All notes are being offered by Roche except the 5.25 percent notes due 2035, which are being issued by Roche subsidiary Genentech.

The amounts to be purchased will be determined in accordance with the acceptance priority level determined by Roche. The amount of the 7 percent notes due 2039 will not exceed an aggregate purchase price of acceptance sublimit of $300 million, Roche said.

The offer will expire at 11:59 p.m. EDT on Dec. 17. JP Morgan Securities and Barclays Capital are the deal managers for the offer.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.